Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?

Atherosclerosis

Volumn 148, Issue 2, 2000, Pages 209-214

  Yudkin, John S ^a   Kumari, Meena ^b   Humphries, Steve E ^b   Mohamed Ali, Vidya ^a  

^a Ctr Diabet Cardiovasc Risk U   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary heart disease; Dyslipidemia; Endothelial dysfunction; Genotype; Insulin resistance; Interleukin 6; Obesity; Stress

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPROTEIN LIPASE; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; BLOOD VISCOSITY; DYSLIPIDEMIA; FOAM CELL; GENOTYPE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; INFECTION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER; MONOCYTE; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; STRESS; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; INTERLEUKIN-6; OBESITY; RISK FACTORS; STRESS; THROMBOSIS; VASCULITIS;

EID: 0033984744     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00463-3     Document Type: Review

References (44)

1. Alexander R.W. Inflammation and coronary artery disease. New Engl. J. Med. 331:1994;468-469.
2. Galis J.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metallo-proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:1994;2493-2503.
3. Kuo C.C., Gown A.M., Benditt E.P., Grayston J.T. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler. Thromb. 13:1993;1501-1504.
4. Patel P., Mendall M.A., Carrington D. et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br. Med. J. 311:1995;711-714.
5. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am. J. Epidemiol. 144:1996;537-547.
6. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl. J. Med. 336:1997;973-979.
7. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265:1990;621-636.
8. Bataille R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 35:1992;982-983.
9. Harris TB, Ferrucci L, Tracy RP et al. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.
10. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obesity 1998; 22:1145-1158.
11. Vallance P., Collier J., Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 349:1997;1391-1392.
12. Tappia P.S., Troughton K.L., Langley-Evans S.C., Grimble R.F. Cigarette smoking influences cytokine production and antioxidant defences. Clin. Sci. 88:1995;485-489.
13. Fantuzzi G., Zheng H., Faggioni R. et al. Effect of endotoxin in IL-1β-deficient mice. J. Immunol. 157:1996;291-296.
14. Marino M.W., Dunn A., Grail D. et al. Characterization of tumor necrosis factor-α deficient mice. Proc. Natl. Acad. Sci. USA. 94:1997;8093-8098.
15. Pang G., Couch L., Batey R., Clancy R., Cripps A. GM-CSF, IL-1α, IL-1β, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1α and TNF-α Clin. Exp. Immunol. 96:1994;437-443.
16. Libby P., Sukhova G., Lee R.T., Galis Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol. 25:1995;S9-S12.
17. DeGraba T.J. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 49:1997;S15-19.
18. Dan K., Gomi S., Inokuchi K. et al. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol. 93:1995;67-72.
19. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects-associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Art Thromb Vasc Biol 1999;19:972-8.
20. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8:1990;253-278.
21. Hardardóttir I., Grünfeld C., Feingold K.R. Effects of endotoxin and cytokines on lipid metabolism. Curr. Opin. Lipidol. 5:1994;207-215.
22. Greenberg A.S., Nordan R.P., McIntosh J., Calvo J.C., Scow R.O., Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin-6 in cancer cachexia. Cancer Res. 52:1992;4113-4116.
23. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in tumor necrosis factor-α and obesity-induced insulin resistance. Science. 271:1996;665-668.
24. Kanemaki T, Kitade H, Kaibori M, et al. Interleukin 1 beta and Interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes, Hepatology 1998;27:1296-303.
25. Bhagat K., Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 96:1997;3042-3047.
26. Romano M., Sironi M., Toniatti C. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 6:1997;1-20.
27. Robinson L.J., Busconi L., Michel T. Agonist-modulated palmitoylation of endothelial nitric oxide synthase. J. Biol. Chem. 270:1995;995-998.
28. Steinberg H.O., Tarshoby M., Monestel R. et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest. 100:1997;1230-1239.
29. Van der Poll T., Levi M., Hack C.E. et al. Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 179:1994;1253-1259.
30. Sawdey M.S., Loskutoff D.J. Regulation of murine type-1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor β J. Clin. Invest. 88:1991;1346-1353.
31. Samad F., Yamamoto K., Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-α and lipopolysaccharide. J. Clin. Invest. 97:1996;37-46.
32. Mohamed-Ali V., Goodrick S., Rawesh A. et al. Human subcutaneous adipose tissue secretes interleukin-6 but not TNF-α in vivo. J. Clin. Endocrinol. Metab. 82:1997;4196-4200.
33. Purohit A., Ghilchik M.W., Duncan L. et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J. Clin. Endocrinol. Metab. 80:1995;3052-3058.
34. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409-2415.
35. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83:1998;847-850.
36. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
37. Zhou D., Kusnecov A.W., Shurin M.R., DePaoli M., Rabin B.S. Exposure to physical and psychological stressors elevates plasma interleukin-6: relationship to the activation of the hypothalamic-pituitary-adrenal axis. Endocrinology. 133:1993;2523-2530.
38. Mohamed-Ali V, Bulmer K, Coppack SW, Pinkney JH. β-Adrenergic regulation of proinflammatory cytokines in humans in vivo, Endocrinology 1998;39:1-4 (abstract).
39. Mastorakos G., Chrousos G.P., Weber J.S. Recombinant interleukin-6 activates the hypothalamo-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 77:1993;1690-1694.
40. Chrousos G.P., Gold P.W. A healthy body in a healthy mind - and vice versa - the damaging power of 'uncontrollable' stress. J. Clin. Endocrinol. Metab. 83:1998;1842-1845.
41. Brunner E.J., Marmot M.G., Nanchahal K. et al. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II Study. Diabetologia. 40:1997;1341-1349.
42. Yudkin JS, Yajnik CS, Mohamed-Ali V, Bulmer K. High levels of circulating pro-inflammatory cytokines and leptin in urban, but not rural, Asian Indians. A potential explanation for increased risk of diabetes and coronary heart disease. Diabetes Care 1999;22:363-4.
43. Fishman D., Faulds G., Jeffery R. et al. Novel polymorphisms in the interleukin-6 gene: their effect on IL-6 transcription, plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:1998;1369-1376.
44. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-88.